Universal Healthcare in the US: What the Real Cost Taught Me

That figure, from a 2018 analysis of Bernie Sanders’ Medicare for All proposal, describes the projected increase in federal budget commitments over ten years. It does not describe the increase in what the United States would spend on healthcare as a whole. In the same analysis, total national health expenditures fell by an estimated $2.054 trillion over that decade once administrative savings and lower payment rates entered the model.

Those are not contradictory numbers. They are numbers describing different fiscal systems.

The question behind how much would universal healthcare cost in the US cannot be answered by pointing at the federal budget and stopping there. The real issue is whether the country would move money from private premiums, employer contributions, household out-of-pocket bills, and insurer administration into public financing—and whether the public system could use its bargaining power to reduce the underlying price of care.

That is where the argument becomes less comfortable for both parties. Universal healthcare would require an enormous transfer of financial responsibility to the federal government. It could also reduce total national healthcare spending. The outcome depends on the design, the payment rules, the tax structure, and the amount of power Congress is willing to take away from insurers, pharmaceutical companies, hospital systems, and high-income providers.

In other words, the price tag is not a single number. It is a fight over who pays, who loses revenue, and who gets to set the terms.

The $32.6 trillion misconception: federal spending is not national spending

The federal budget is not the same thing as the national economy.

Under the current US healthcare system, households and employers pay premiums to private insurers. Patients pay deductibles, copayments, and coinsurance. Employers treat health benefits as part of compensation. State governments finance Medicaid. Federal programs cover Medicare, Medicaid, veterans, and other public obligations. Insurers spend money processing claims, negotiating networks, marketing plans, managing utilization, and generating profits. Hospitals and drug companies set prices within a fragmented market that rewards leverage rather than restraint.

A Medicare for All system would shift much of that spending into a federal program. The government would collect substantially more revenue and make substantially more healthcare payments. That would make federal spending rise sharply, even if the total amount spent across the US economy fell.

The 2018 Mercatus Center analysis estimated that federal budget commitments would increase by $32.6 trillion over the first ten years of full implementation. Critics often present that number as if it means Americans would spend $32.6 trillion more on healthcare. That is not what the study said. Its model also estimated a $2.054 trillion reduction in net national health expenditures, based on lower administrative costs and lower provider payment rates.

The distinction matters because the current system already collects the money. It just collects it through a maze of premiums, employer payments, public programs, medical debt, and direct household spending. The federal government’s ledger does not capture the full cost of that maze.

The Congressional Budget Office made the same basic point from a different angle. Its analysis of five single-payer design options projected that federal subsidies for healthcare in 2030 could increase by $1.5 trillion to $3.0 trillion annually compared with current law. That is an extraordinary increase in federal responsibility. It is also not a forecast that national healthcare spending must rise by the same amount.

Depending on choices about cost sharing and provider payment rates, the CBO projected that total national health expenditures in 2030 could range from a $0.7 trillion decrease to a $0.3 trillion increase relative to current law.

That is a very wide range. It is also a useful correction to the political theater. The main fiscal question is not whether Washington would spend more. Washington would. The question is whether the country would spend more overall—and who would retain the money that a public system would otherwise redirect.

A universal system would not make healthcare free. It would make the bill visible, collective, and politically unavoidable.

The current arrangement hides its price across paychecks, premiums, tax exclusions, unpaid bills, and foregone care. A public system would put more of the bill on the federal balance sheet. That visibility would create political conflict, but it would also make the distribution of costs easier to examine.

The administrative machine is expensive because it is designed to extract

The United States does not merely pay for medical treatment. It pays for the bureaucracy required to determine whether treatment will be paid for.

That bureaucracy includes insurer billing departments, hospital coding operations, prior authorization systems, claims appeals, network management, broker commissions, plan marketing, eligibility administration, compliance teams, and the software infrastructure required to make dozens of payers interact with thousands of providers. Every layer takes money. Every layer also creates opportunities for denial, delay, and strategic confusion.

This is not an accidental malfunction. It is a business model.

A fragmented insurance market allows companies to compete by restricting access as much as by improving care. Narrow networks, high deductibles, formularies, utilization controls, and complex eligibility rules can reduce an insurer’s exposure to claims. They also move work onto patients and clinicians. The patient spends hours fighting a denial. The doctor’s office hires staff to submit another form. The hospital maintains a financial department dedicated to collecting from people who cannot afford the balance.

The system counts much of this as economic activity. That does not make it socially productive.

The Yale-led analysis of a single-payer system estimated that universal coverage could reduce national health spending by approximately 13%, or more than $450 billion per year, while saving thousands of lives annually. The savings in that model came from the basic mechanisms that private insurers and large providers resist: lower administrative overhead, lower drug prices, and stronger control over provider payments.

The Political Economy Research Institute at the University of Massachusetts Amherst reached a less dramatic but still substantial conclusion. Its analysis estimated that Medicare for All could reduce total US healthcare spending by nearly 10%, producing roughly $5 trillion in savings over ten years, while covering all residents.

These estimates do not prove that every single-payer proposal would generate identical savings. They show what becomes financially possible when the system stops treating every insurer, billing contractor, and pharmaceutical intermediary as an indispensable component of care.

The central leverage comes from scale. A national public insurer could negotiate drug prices across the entire covered population. It could standardize billing. It could eliminate the need for providers to maintain separate administrative systems for multiple commercial plans. It could replace premiums with a public financing structure that does not punish people for changing jobs or losing income.

But administrative savings are not magic. A public program still needs oversight, fraud controls, claims processing, clinical standards, and regional management. The argument is not that government administration costs nothing. The argument is that the United States currently pays for several overlapping systems whose complexity serves corporate revenue more reliably than patient care.

The Medicare for All price tag depends on who loses bargaining power

The most consequential design choice is not the font on the legislation. It is the payment schedule.

Hospitals, physicians, nursing facilities, and pharmaceutical manufacturers do not receive the same rates from every payer. Commercial insurers often pay providers more than Medicare does. Large hospital systems use market concentration to demand higher rates, especially when patients have no realistic alternative. Drug companies rely on the absence of comprehensive federal negotiation to protect prices that would face serious downward pressure in a unified purchasing system.

A universal healthcare plan can lower total spending only if it changes those terms.

The CBO’s projections show why the results vary. Different single-payer models produce different outcomes depending on provider reimbursement rates, cost sharing, covered services, and the extent of long-term care. If the government pays providers close to current commercial rates, the savings shrink or disappear. If it imposes rates closer to existing public programs, spending can fall—but providers with high labor costs, large debt obligations, or inflated executive compensation may face a financial shock.

That conflict does not make the model incoherent. It identifies the real political battle.

Hospitals often describe commercial payment rates as necessary to compensate for underpayment by public programs. Some of that argument reflects genuine operating pressures, particularly for rural hospitals and safety-net institutions. But the same market also supports hospital consolidation, aggressive expansion into lucrative specialties, executive compensation packages, and investment strategies that treat healthcare infrastructure as an asset class.

A serious universal system would need to distinguish between clinical capacity and rent extraction. Cutting payment rates without protecting under-resourced facilities could produce closures, workforce shortages, or reduced access in regions that already lack care. Preserving every existing revenue stream, meanwhile, would leave the country paying for universal coverage without capturing the savings that make it fiscally defensible.

The same logic applies to pharmaceuticals. Lower prices would help households and public budgets, but they would reduce the revenue available to manufacturers. The industry would respond with familiar claims about innovation and research. Some of those claims deserve scrutiny rather than dismissal. Public financing already supports a significant share of biomedical research, and high prices do not automatically translate into equitable access or socially necessary innovation. A system that wants lower prices must decide how it will fund research and development without allowing monopoly pricing to function as the default subsidy.

Cost sharing creates another fault line.

A plan with no premiums but substantial deductibles and copayments would technically offer universal coverage while preserving financial barriers at the point of care. A plan with comprehensive benefits and minimal cost sharing would offer stronger protection but require more public revenue. The distributional consequences would differ sharply.

For a wealthy household, a new tax may cost more than current premiums but remain manageable. For a low-income household, eliminating premiums and medical bills could represent a major improvement even if the tax system becomes more progressive. For an employer, the transition could replace an expensive benefit obligation with a payroll or corporate tax. For an insurer, it could eliminate a core revenue stream entirely.

This is why debates about the Medicare for All budget often become debates about class power disguised as accounting. The same dollar can appear as a tax increase to one actor, a premium reduction to another, and a lost profit margin to a third.

The main design levers

The fiscal result turns on a small number of decisions:

• Provider payment rates: Higher rates protect existing institutions but reduce potential savings. Lower rates create more fiscal room but require safeguards for hospitals and clinicians operating in weak markets.
• Drug price negotiation: A national purchaser can use its scale to reduce prices, but only if legislation permits genuine bargaining rather than symbolic negotiation.
• Cost sharing: Lower deductibles and copayments improve access and reduce medical debt, while higher cost sharing shifts more of the system’s burden back onto patients.
• Covered services: Dental, vision, hearing, prescription drugs, reproductive care, and long-term care can substantially change the budget.
• Transition speed: A rapid transition could capture savings sooner but create greater disruption for workers and institutions tied to private insurance.
• Tax financing: The exact tax rates cannot be responsibly stated without a specific bill and financing structure. The distribution matters as much as the total revenue.

Any analysis that presents a universal healthcare price tag without naming these choices is not doing fiscal analysis. It is selling a political conclusion with a large number attached.

Why the projections vary so wildly

The research does not deliver one clean answer because the proposals do not describe one clean system.

The CBO analyzed five possible single-payer designs rather than declaring a single universal healthcare cost. That was the correct approach. A plan with comprehensive benefits, no cost sharing, generous provider rates, and long-term care coverage will produce a different budget from a plan with narrower benefits, moderate patient payments, and lower reimbursement.

RAND’s 2019 analysis illustrates the point. It examined a national Medicare for All plan with comprehensive benefits and long-term care and estimated total health expenditures at $3.89 trillion, a 1.8% increase compared with spending under current law for that year. That result sits beside other studies projecting large reductions. The difference does not necessarily indicate that one institution understands arithmetic and the others do not. It reflects assumptions about what the program covers and how it pays for care.

The methodological disputes are real. Researchers must estimate how many people will use care once financial barriers fall. They must predict how providers will respond to new payment rules. They must account for administrative savings while recognizing that implementation itself creates costs. They must model drug prices, workforce capacity, long-term care demand, and changes in employer compensation.

The public debate usually strips away all of that complexity and keeps whichever number best serves the speaker.

Opponents cite federal spending increases and imply that the nation would add tens of trillions of dollars to its existing healthcare burden. Supporters cite projected savings and sometimes imply that the transition would be painless. Both shortcuts fail.

A credible analysis must hold several facts together:

1. Federal spending would increase dramatically. The government would assume costs currently distributed across private insurers, employers, state programs, and households.

2. Total national spending could fall. Administrative savings, lower drug prices, and reduced provider reimbursement can offset the federal increase.

3. The result depends on implementation. The CBO’s projected range—from a $0.7 trillion annual reduction to a $0.3 trillion annual increase in 2030—shows how much the design matters.

4. The transition would redistribute income and power. Some households would pay more through taxes, while others would save on premiums and out-of-pocket costs. Insurers and high-priced providers would lose revenue.

5. Coverage expansion creates real demand. If millions of people seek care they previously avoided, the system must expand its workforce and facilities. The current research does not settle how regional capacity constraints would affect wait times or unmet demand.

The last point deserves more attention. Universal insurance does not instantly create physicians, nurses, dentists, clinics, operating rooms, or home-care workers. Coverage can expose shortages that the current system conceals by pricing people out. A patient who never schedules an appointment because the deductible is unaffordable does not appear in a waiting-time statistic. Once the financial barrier disappears, the demand becomes visible.

That is not an argument against universal care. It is an argument for treating healthcare as infrastructure rather than as a card distributed by an insurance company. The country would need investment in training, public and rural hospitals, primary care, mental health services, disability support, and long-term care. A cheaper financing system still requires material capacity.

The hardest part of universal healthcare is not proving that the arithmetic can work. It is forcing powerful institutions to surrender the revenue streams that make the arithmetic work.

The real trade-off is public financing versus private extraction

The phrase “cost of implementing Medicare for All” often suggests a one-time construction project: pass a law, fund a program, issue insurance cards, and wait for savings. That is not how this transition would operate.

The system would have to move from an employment-linked insurance model to a public entitlement. That means replacing or restructuring employer-sponsored coverage, Medicaid arrangements, Medicare benefits, Affordable Care Act subsidies, and the private insurance market. Workers in insurance administration would need transition support. Providers would need new billing systems. States would need to revise their role. Federal agencies would need the authority and capacity to administer a program larger than any existing public insurer.

Those costs matter. So do the costs of not changing the system.

The United States currently spends $5.3 trillion on healthcare, or about $15,474 per person, according to the 2024 baseline cited in the research, representing 18% of GDP. This is not a country choosing between expensive universal healthcare and an inexpensive status quo. It is a country already paying an enormous amount for a system that leaves people uninsured or underinsured, rations care by income, and directs a substantial share of resources into administration and profit.

The baseline is already a policy decision. So is the medical debt. So are unpaid hospital bills, delayed treatment, employer lock-in, and the public money used to stabilize private institutions when their business models fail.

The choice is therefore not simply whether to spend more or less. It is whether to spend collectively through taxation and public budgeting, or continue paying through a fragmented system that gives private actors the power to extract at every stage.

That does not make every public plan automatically superior. Public programs can underpay workers, impose bureaucratic barriers, and fail to distribute resources fairly. Government agencies can become vulnerable to austerity politics. A federal guarantee can coexist with racial, regional, and disability-based inequities if lawmakers design the benefits narrowly or allow local providers to disappear.

A progressive healthcare policy must therefore ask more than whether the ledger balances. It must ask who receives care, who performs it, who controls the infrastructure, and whether the system expands people’s actual capacity to live healthy lives.

Universal coverage is not the same as universal access. A card does not build a clinic. A tax does not train a nurse. A federal entitlement does not, by itself, end segregation in healthcare or repair decades of disinvestment. But private fragmentation has not solved those problems either. It has often converted them into profitable scarcity.

The fiscal case for single payer rests on using public leverage where private markets have failed: purchasing drugs at lower prices, simplifying administration, removing premiums from employment, and reducing the ability of providers and insurers to charge whatever concentrated markets will tolerate.

The political case rests on refusing to treat avoidable illness and medical bankruptcy as natural features of American life.

What the numbers actually teach

The phrase “universal healthcare cost” makes the issue sound like a technical query. The answer is political because the cost depends on the rules imposed on money and power.

The strongest evidence does not support a simplistic promise that every Medicare for All model will save the same amount. It supports a narrower and more defensible conclusion: the United States could expand coverage to everyone while keeping total national healthcare spending roughly stable or reducing it, but only by making aggressive choices about administrative waste, drug prices, provider payments, and cost sharing.

That is why opponents focus on federal spending. They want the public to see the transfer while ignoring the private payments it replaces. That is why some supporters focus only on projected savings. They want the public to see efficiency while minimizing the disruption and institutional resistance required to achieve it.

The honest account contains both.

A federal spending increase of $32.6 trillion over ten years would represent a historic expansion of public responsibility. It would also represent a replacement of spending that currently flows through employers, households, insurers, and state programs. The same model’s estimated $2.054 trillion reduction in national health expenditures indicates that the financing shift could produce system-wide savings. Yale researchers estimated a reduction of roughly 13%. PERI estimated nearly 10%. RAND found a modest increase under a broader design. The CBO found outcomes ranging from substantial savings to a modest increase.

Those results are not a verdict against universal healthcare. They are a warning against pretending that policy design is a footnote.

If lawmakers preserve inflated provider rates, leave drug companies with monopoly pricing, and build a public program around high cost sharing, the savings will weaken. If they negotiate forcefully, simplify payment, finance care progressively, and protect the institutions that communities actually need, the country can redirect money away from extraction and toward treatment.

We should stop asking whether universal healthcare has a price. Everything has a price, including the system we already have. The question is who pays that price, who profits from it, and whether the payment produces care rather than paperwork.

The data taught me that the federal budget number is real but incomplete. The potential savings are plausible but conditional. The human stakes are immediate, while the transition risks are material and manageable only through deliberate public investment.

The central obstacle is not a lack of money. The United States already spends enough to fund a far more comprehensive system. The obstacle is that too much of that money currently sits behind private gatekeepers with every incentive to preserve scarcity.

Universal healthcare would cost the public treasury more. It could cost the nation less. Whether it does depends on whether policymakers treat healthcare as a right supported by public infrastructure—or as another extraction market that happens to involve human bodies.